About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Apotex, Inc. et al. v. Teva Pharmaceutical Industries, Ltd. et al.
0:13-cv-60601; filed March 14, 2013 in the Southern District of Florida
• Plaintiffs: Apotex, Inc.; Apotex Corp.
• Defendants: Teva Pharmaceutical Industries, Ltd.; Teva Pharmaceuticals USA, Inc.
Infringement of U.S. Patent No. 6,531,486 ("Pharmaceutical Compositions Comprising Quinapril Magnesium," issued March 11, 2003) based on Teva's manufacture of generic quinapril hydrochloride products (used to treat hypertension). View the complaint here.
Bayer Intellectual Property GmbH et al. v. Rea
1:13-cv-00324; filed March 12, 2013 in the Eastern District of Virginia
• Plaintiffs: Bayer Intellectual Property GmbH; Bayer Pharma Aktiengesellschaft
• Defendant: Hon. Teresa Stanek Rea
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,273,876 ("Medicaments Containing Vardenafil Hydrochloride Trihydrate," issued September 25, 2012). View the complaint here.
Janssen Products, L.P. et al. v. Hetero Drugs, Ltd. et al.
2:13-cv-01444; filed March 8, 2013 in the District Court of New Jersey
• Plaintiffs: Janssen Products, L.P.; Janssen R&D Ireland
• Defendants: Hetero Drugs, Ltd.; Unit III; Invagen Pharmaceuticals, Inc.
Infringement of U.S. Patent Nos. 7,126,015 ("Method for the Preparation of Hexahydro-furo-[2,3-b]furan-3-ol," issued October 24, 2006) and 7,595,408 ("Methods for the Preparation of (3R,3aS,6aR)hexahydro-furo[2,3-b]furan-3-ol," issued September 29, 2009) in conjunction with defendants' filing of an ANDA to manufacture a generic version of Janssen's Prezista® (darunavir, used to treat human immunodeficiency virus (HIV-1) infection). View the complaint here.
Novartis Pharmaceuticals Corp. et al. v. Alvogen Pine Brook Inc. et al.
1:13-cv-00370; filed March 7, 2013 in the District Court of Delaware
• Plaintiffs: Novartis Pharmaceuticals Corp.; Novartis AG; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; LTS Lohmann Therapie-Systeme AG
• Defendants: Alvogen Pine Brook Inc.; Alvogen Group Inc.
Novartis Pharmaceuticals Corp. et al. v. Actavis Inc. et al.
1:13-cv-00371; filed March 7, 2013 in the District Court of Delaware
• Plaintiffs: Novartis Pharmaceuticals Corp.; Novartis AG; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; LTS Lohmann Therapie-Systeme AG
• Defendants: Actavis Inc.; Watson Pharmaceuticals Inc.; Watson Laboratories Inc.; Watson Pharma Inc.
The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 6,316,023 ("TTS Containing an Antioxidant," issued November 13, 2001) and 6,335,031 (same title, issued January 1, 2002) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Novartis' Exelon® Patch (rivastigmine tartrate, used to treat mild to moderate dementia of the Alzheimer's type, and mild to moderate dementia associated with Parkinson's disease). View the Alvogen complaint here.
Merck, Sharp & Dohme Corp. et al. v. Hetero USA Inc. et al.
1:13-cv-01402; filed March 7, 2013 in the District Court of New Jersey
• Plaintiffs: Merck, Sharp & Dohme Corp.; Bristol-Myers Squibb Co.; Bristol-Myers Squibb Pharma Co.
• Defendants: Hetero USA Inc.; Hetero Labs Ltd. Unit-III
Infringement of U.S. Patent Nos. 6,639,071 ("Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one," issued October 28, 2003) 6,939,964 (same title, issued September 6, 2005), and 6,673,372 ("Crystalline Efavirenz," filed January 6, 2004) following a Paragraph IV certification as part of Hetero's filing of an ANDA to manufacture a generic version of BMS' Sustiva® (efavirenz, used to treat HIV infection). View the complaint here.